GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Particularly if you tend not to have vaccine side effects, getting routine shots in one go may be a convenient option.

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Officials are encouraging Connecticut residents to get their updated shots before the holiday season begins. Unlike COVID-19 ...